Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. 2015

Maike Buchner, and Eugene Park, and Huimin Geng, and Lars Klemm, and Johanna Flach, and Emmanuelle Passegué, and Hilde Schjerven, and Ari Melnick, and Elisabeth Paietta, and Dragana Kopanja, and Pradip Raychaudhuri, and Markus Müschen
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California 94143, USA.

Despite recent advances in the cure rate of acute lymphoblastic leukaemia (ALL), the prognosis for patients with relapsed ALL remains poor. Here we identify FOXM1 as a candidate responsible for an aggressive clinical course. We show that FOXM1 levels peak at the pre-B-cell receptor checkpoint but are dispensable for normal B-cell development. Compared with normal B-cell populations, FOXM1 levels are 2- to 60-fold higher in ALL cells and are predictive of poor outcome in ALL patients. FOXM1 is negatively regulated by FOXO3A, supports cell survival, drug resistance, colony formation and proliferation in vitro, and promotes leukemogenesis in vivo. Two complementary approaches of pharmacological FOXM1 inhibition-(i) FOXM1 transcriptional inactivation using the thiazole antibiotic thiostrepton and (ii) an FOXM1 inhibiting ARF-derived peptide-recapitulate the findings of genetic FOXM1 deletion. Taken together, our data identify FOXM1 as a novel therapeutic target, and demonstrate feasibility of FOXM1 inhibition in ALL.

UI MeSH Term Description Entries
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071316 Forkhead Box Protein O3 A forkhead box transcription factor and transcriptional activator which triggers type 1 programmed cell death (APOPTOSIS) in the absence of APOPTOSIS INHIBITING PROTEINS, including neuronal cell death induced by OXIDATIVE STRESS. It recognizes and binds to the DNA sequence 5'-(AG)TAAA(TC)A-3' and also functions in post-transcriptional regulation of the c-MYC PROTO-ONCOGENE. FOXO3 Protein,Forkhead in Rhabdomyosarcoma-Like 1 Protein,Forkhead in Rhabdomyosarcoma Like 1 Protein,Protein, FOXO3
D000072278 Forkhead Box Protein M1 A forkhead box transcription factor that is expressed primarily in adult organs which contain proliferating cells such as the thymus, testis, ovary, and small intestine. It controls the expression of CELL CYCLE genes essential for DNA REPLICATION and MITOSIS, and also functions in DNA REPAIR. FOXM1 Protein
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Maike Buchner, and Eugene Park, and Huimin Geng, and Lars Klemm, and Johanna Flach, and Emmanuelle Passegué, and Hilde Schjerven, and Ari Melnick, and Elisabeth Paietta, and Dragana Kopanja, and Pradip Raychaudhuri, and Markus Müschen
February 2019, British journal of haematology,
Maike Buchner, and Eugene Park, and Huimin Geng, and Lars Klemm, and Johanna Flach, and Emmanuelle Passegué, and Hilde Schjerven, and Ari Melnick, and Elisabeth Paietta, and Dragana Kopanja, and Pradip Raychaudhuri, and Markus Müschen
June 2005, British journal of haematology,
Maike Buchner, and Eugene Park, and Huimin Geng, and Lars Klemm, and Johanna Flach, and Emmanuelle Passegué, and Hilde Schjerven, and Ari Melnick, and Elisabeth Paietta, and Dragana Kopanja, and Pradip Raychaudhuri, and Markus Müschen
February 2015, European journal of haematology,
Maike Buchner, and Eugene Park, and Huimin Geng, and Lars Klemm, and Johanna Flach, and Emmanuelle Passegué, and Hilde Schjerven, and Ari Melnick, and Elisabeth Paietta, and Dragana Kopanja, and Pradip Raychaudhuri, and Markus Müschen
March 2019, British journal of haematology,
Maike Buchner, and Eugene Park, and Huimin Geng, and Lars Klemm, and Johanna Flach, and Emmanuelle Passegué, and Hilde Schjerven, and Ari Melnick, and Elisabeth Paietta, and Dragana Kopanja, and Pradip Raychaudhuri, and Markus Müschen
January 2013, British journal of haematology,
Maike Buchner, and Eugene Park, and Huimin Geng, and Lars Klemm, and Johanna Flach, and Emmanuelle Passegué, and Hilde Schjerven, and Ari Melnick, and Elisabeth Paietta, and Dragana Kopanja, and Pradip Raychaudhuri, and Markus Müschen
January 2014, Journal of cancer therapy,
Maike Buchner, and Eugene Park, and Huimin Geng, and Lars Klemm, and Johanna Flach, and Emmanuelle Passegué, and Hilde Schjerven, and Ari Melnick, and Elisabeth Paietta, and Dragana Kopanja, and Pradip Raychaudhuri, and Markus Müschen
May 2019, Cancer research,
Maike Buchner, and Eugene Park, and Huimin Geng, and Lars Klemm, and Johanna Flach, and Emmanuelle Passegué, and Hilde Schjerven, and Ari Melnick, and Elisabeth Paietta, and Dragana Kopanja, and Pradip Raychaudhuri, and Markus Müschen
April 2020, Cancer chemotherapy and pharmacology,
Maike Buchner, and Eugene Park, and Huimin Geng, and Lars Klemm, and Johanna Flach, and Emmanuelle Passegué, and Hilde Schjerven, and Ari Melnick, and Elisabeth Paietta, and Dragana Kopanja, and Pradip Raychaudhuri, and Markus Müschen
May 2022, Medical engineering & physics,
Maike Buchner, and Eugene Park, and Huimin Geng, and Lars Klemm, and Johanna Flach, and Emmanuelle Passegué, and Hilde Schjerven, and Ari Melnick, and Elisabeth Paietta, and Dragana Kopanja, and Pradip Raychaudhuri, and Markus Müschen
June 1989, British journal of haematology,
Copied contents to your clipboard!